Renagel

Selected form

Sevelamer

Method of action: All Other Therapeutic Products, Hypophosphatemic

Treatment option: Hemodialysis, Hyperphosphatemia, Peritoneal Dialysis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Renagel

Property	Description
Active ingredient	Sevelamer hydrochloride
Form	Film-coated tablet (Oral administration)
Pharmacological class	Phosphate binder (Non-metallic agent)
Common use	Management of hyperphosphatemia
Origin	Synthetic, amine-based polymer

Renagel is a prescription medication fundamentally classified as a phosphate binder, primarily used to manage dangerously high phosphate levels in the body, a condition medically termed hyperphosphatemia. This medication belongs to a specialized group of gastrointestinal agents that act locally within the digestive system, aiming to control serum phosphate concentration. Its overall purpose is to support individuals, particularly adult patients with Chronic Kidney Disease (CKD) and those on maintenance dialysis, in maintaining appropriate mineral balance.

What Type of Drug is Renagel and What is its Composition?

The active ingredient in Renagel is Sevelamer hydrochloride, which is defined chemically as a synthetic, amine-based polymer derived from Poly(allylamine hydrochloride). Renagel is distinguished as a non-metallic phosphate binder, differentiating it from older agents that incorporate calcium or aluminum. The medication is a single-ingredient product supplied as a film-coated tablet intended for oral administration, with the polymer contained within a hydrophilic polymeric matrix.

The unique chemical structure of the Sevelamer hydrochloride polymer provides a cationic charge, essential for its binding function. Because this substance is a non-absorbed polymer, its entire action is strictly localized to the gastrointestinal tract, ensuring it fulfills its purpose without entering the bloodstream. This property of non-systemic action is a key differentiating factor in its pharmacological profile.

Core Purpose: Managing Phosphate Levels in CKD

The core purpose of Renagel is to reduce the body's absorption of dietary phosphate to control and maintain balanced levels. By acting like a specialized sponge, the drug utilizes its unique mechanism to bind with phosphate from food, preventing it from contributing to dangerous levels of hyperphosphatemia. This polymer-based strategy provides phosphate-binding capacity for patients with renal failure.

This phosphate capture mechanism is crucial for the target audience of adult patients with End-Stage Renal Disease (ESRD) and those undergoing various forms of dialysis. By facilitating the elimination via feces of the bound phosphate, Renagel addresses a vital aspect of chronic kidney care where the kidneys are no longer capable of effectively managing the body's mineral balance on their own.

What side effects are possible with Renagel?

Adverse reaction scope

Key Adverse Reactions: Adverse reactions associated with Renagel (sevelamer hydrochloride) primarily involve the Gastrointestinal system, and they are the most common reason for treatment discontinuation.

Common to Very Common Adverse Reactions (ge 1%): Vomiting (Very Common), Nausea (Very Common), Diarrhea (Very Common), Dyspepsia (Very Common), Abdominal pain, Flatulence, Constipation, Peritonitis (in peritoneal dialysis patients), Upper respiratory tract infection, Hypertension, and headache.

Serious Adverse Reactions: Serious post-marketing reports include cases of bowel obstruction, intestinal perforation, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and dysphagia (difficulty swallowing) or esophageal tablet retention, some requiring hospitalization and surgical intervention.

Safety Considerations and Restrictions

Contraindications: Renagel is contraindicated in patients with pre-existing bowel obstruction or hypophosphatemia (low blood phosphate levels), as well as in patients with a known hypersensitivity to sevelamer hydrochloride or its excipients.

Population-Specific Caution: Caution is advised, and safety and efficacy have not been established, in patients with severe gastrointestinal motility disorders, severe constipation, or major GI tract surgery. The tablet formulation should be swallowed whole and not crushed or chewed, with the suspension formulation considered for patients with a history of swallowing disorders.

Safety Monitoring: Due to the drug's mechanism of action, serum levels of fat-soluble vitamins (D, E, and K) and folic acid should be monitored, as Renagel may reduce their absorption. Serum bicarbonate and chloride levels should also be monitored.

Drug Interactions: The timing of administration must be separated from certain other oral medications, such as ciprofloxacin and mycophenolate mofetil, to avoid a clinically significant reduction in their absorption.

Overdose and Emergency Response

Official Overdose Information and Emergency Actions

The most authoritative regulatory documents, such as the U.S. FDA Prescribing Information and the European Medicines Agency (EMA) Summary of Product Characteristics, provide specific guidance regarding overdose of sevelamer hydrochloride (Renagel).

Overdose Documentation: The EMA regulatory documents explicitly state that no case of overdose has been reported for Renagel. Clinical studies have administered high doses, such as up to 14 grams per day for eight days to healthy volunteers, without observing undesirable effects, suggesting a low potential for acute toxicity.
Symptoms of Overdose: Specific clinical manifestations or symptom clusters caused by an overdose are not documented in the official regulatory sections, as no overdose cases have been reported.
Population and Conditions: No population or condition-specific overdose risks are explicitly defined in the official overdosage sections of the regulatory labeling.

When to Seek Immediate Medical Help

Official patient information derived from regulatory sources emphasizes immediate action in case a dose greater than prescribed is taken. This guidance is procedural and applies even in the absence of documented overdose symptoms:

Overdose Context	Required Emergency Action (Official Regulatory Phrasing)
If too much is taken (overdose)	Seek emergency medical attention or call the Poison Help line at the designated national number.

In summary, while there are no documented physiological presentations of overdose, regulatory documents direct users to seek emergency medical attention as a necessary precaution if they believe they have taken an excessive amount.

Therapeutic Uses of Renagel

Renagel (Sevelamer hydrochloride) is commonly used to help with metabolic complications that arise in adult patients with Chronic Kidney Disease (CKD). It is relevant for easing symptoms across therapeutic domains. The primary indication is for the control of serum phosphorus in patients with CKD on dialysis.

The medication is commonly used to help with hyperphosphatemia (significantly elevated blood phosphate levels), assists with managing symptom clusters related to soft-tissue mineral manifestations, and supports the patient during episodes associated with long-term systemic stress in the context of End-Stage Renal Disease (ESRD)**.

“It plays a role in managing symptoms related to systemic imbalance, where additional symptomatic support is needed.”

Renagel is used for managing symptoms related to systemic imbalance and may assist with managing serum phosphorus concentration. It is relevant in clinical settings marked by increased discomfort or tension, and helps improve day-to-day comfort during symptomatic periods. This supportive therapeutic benefit contributes to easing the overall symptom load and assists with maintaining functional stability.

Quick Fact: Support for Uremic Pruritus Renagel is relevant for easing distressing manifestations such as chronic, generalized itching (pruritus) which create noticeable physiological strain.

Eligibility and Restrictions for Use

Renagel (sevelamer hydrochloride) is strictly defined by regulatory agencies for use in a specific patient population, primarily based on the presence of kidney disease and the absence of certain gastrointestinal conditions.

Eligibility and Non-Eligibility Status

Classification	Eligible Population/Constraint
Allowed Use	Patients with Chronic Kidney Disease (CKD) who are on dialysis (hemodialysis or peritoneal dialysis).
Contraindicated	Patients with bowel obstruction, hypophosphatemia (abnormally low blood phosphate), or known hypersensitivity to sevelamer hydrochloride or its ingredients.
Use Not Established/Caution	CKD patients who are not on dialysis; safety and efficacy have not been studied.
Age Restriction	Pediatric patients (under 18 years of age); safety and efficacy have not been established.
Special Caution	Patients with dysphagia, swallowing disorders, severe gastrointestinal motility disorders (including severe constipation), or a history of major GI tract surgery were excluded from clinical trials and must be monitored carefully.

Official documents indicate that the safety of Renagel has not been established in pregnant or nursing women, and it should only be administered if the potential benefit outweighs the risk.

What should I know about interactions with other medicines?

Renagel (Sevelamer hydrochloride) interacts with other products primarily through a pharmacokinetic interaction where it physically binds to substances in the digestive tract. This binding results in reduced oral bioavailability of co-administered medicines. The drug is not absorbed systemically and has no documented interactions with metabolic pathways like CYP450 enzymes or drug transporters.

Interactions Affecting Drug Exposure

Co-administration may result in a reduction of plasma concentrations for several critical oral medicines, as noted in regulatory prescribing information. This includes the antibiotic Ciprofloxacin and the immunosuppressants Mycophenolate Mofetil (MMF), Cyclosporine, and Tacrolimus. Additionally, taking the medicine with Levothyroxine has been associated with increased TSH levels, reflecting reduced Levothyroxine exposure.

Administration Timing Requirements

To mitigate the risk of reduced exposure, regulatory documents mandate specific administration separation. Ciprofloxacin must be administered at least 2 hours before or 6 hours after the administration of Renagel. Similarly, Mycophenolate Mofetil (MMF) must be administered at least 2 hours before. For other oral medicines where reduced bioavailability is clinically significant, official labeling advises that a separation of dosing time should be considered.

Interactions with Supplements

The binding activity of the drug may also affect the absorption of certain supplements. Official labels note that Renagel may lead to decreased serum levels of the fat-soluble Vitamins D, E, and K, as well as Folic Acid.

Mechanism of Action

The mechanism of sevelamer hydrochloride is purely physicochemical, defined by its non-systemic action localized to the gastrointestinal lumen. Renagel is a non-absorbed polymer containing numerous amine groups that become positively charged (cationic) within the digestive tract environment.

This cationic charge drives an ionic binding cascade, enabling the drug to electrostatically sequester negatively charged dietary phosphate ions ( PO4^3-). This interaction forms a large, insoluble polymer-phosphate complex, which is non-absorbable and effectively interrupts the intestinal phosphate absorption pathway. The mechanism thus diverts the phosphate from the body's circulation.

Because the drug remains confined to the gut, the complex is removed entirely via fecal excretion, leading directly to a reduction in systemic phosphate concentration. This mechanism is strictly limited to newly ingested phosphate; it does not reduce pre-existing systemic phosphate concentrations and is entirely dependent on temporal synchronicity with food intake.

Dosage and Administration Information

How to Use Renagel (Sevelamer Hydrochloride)

The usage protocol for Renagel includes its route of administration, timing, and dosage schedule. The medication is an oral preparation supplied as a film-coated tablet and is utilized as part of a long-term, continuous therapy plan to manage chronic hyperphosphatemia.

Official Administration Guidelines

Instruction	Detail
Route	Oral administration only.
Timing	Must be taken with meals to facilitate binding of dietary phosphate.
Dosing Frequency	Administered three times daily (TID), synchronized with main meals.
Initial Dose	The standard starting dose is between 800 mg and 1,600 mg per meal.
Maintenance Dose	Doses are adjusted, or titrated, to achieve target serum phosphate levels, typically ranging from 800 mg up to 4,000 mg per meal.

Procedural Instructions and Constraints

To ensure proper administration, the film-coated tablets must be swallowed whole and should not be crushed, broken, or chewed. This instruction maintains the tablet’s structural integrity necessary for its intended action. The use protocol for the general adult population, including older adults, does not specify a separate dose adjustment. Additionally, Renagel is not indicated for use in pediatric patients.

If a dose is missed, the protocol is to skip that dose entirely and resume the regimen by taking the next scheduled dose with the next meal; taking two doses at once to compensate for a missed dose is not the stated procedure. This standardized protocol ensures continuous management of phosphate levels as dictated by the chronic nature of the condition being managed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Renagel

Evidence for Use in Hyperphosphatemia in Dialysis Patients

This section will summarize the available research, including randomized controlled trials (RCTs) and comparative studies, that have examined the effect of the medication on changes in serum phosphorus levels in adults with Chronic Kidney Disease (CKD) who are receiving dialysis. The review will cover the types of populations studied and the objective laboratory measures used by researchers.

Studies explored this medication in adult populations with chronic kidney disease who are receiving hemodialysis or peritoneal dialysis. This medication was studied for how it may affect serum phosphorus and calcium values over defined time intervals. Findings describe patterns observed where use of this medication was associated with different patterns in phosphorus levels within the observed populations. These findings help contextualize how patients' phosphorus levels evolved during the trials. The evidence contributes to understanding patterns in laboratory outcomes, but the full scope of measured changes beyond phosphorus levels is still being explored.

Comparison Studies with Other Phosphate Binders

Comparative research has explored this medication against other commonly used phosphate binders, particularly those containing calcium. These studies examined outcomes related to systemic imbalance, such as changes in serum phosphorus and calcium levels. Data show patterns related to how the different treatments were observed in patients, particularly how serum phosphorus levels evolved relative to predefined laboratory ranges. Comparative evidence is lacking for all potential alternative phosphate management strategies.

Long-term Studies and Follow-up

Studies monitored patients over longer time periods (sometimes one year or more) to see how the management of phosphorus levels developed over time. These extended studies described patterns observed in the studies related to stability in serum phosphorus levels over time, and tracked the serum phosphorus levels of patients throughout the follow-up period. While some data exist for extended use, the follow-up durations were limited for understanding effects beyond several years.

What is Still Uncertain About Renagel

While research has explored the use of the medication in patients on dialysis, the evidence for this medication in earlier stages of CKD (patients who are not yet receiving dialysis treatment) is still emerging. Furthermore, specific, long-term data on how certain vitamin levels evolve while using this medication are not fully established. Certainty remains low regarding the exact long-term changes observed in nutritional status, and research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Renagel (FAQ)

Q: What happens if I miss a dose of Renagel?

If a dose of Renagel is missed, regulatory information advises patients to skip that dose entirely. Official guidance indicates that two doses should not be taken at once to compensate. Instead, the patient should wait and take the next scheduled dose with the next meal as directed.

Q: Can Renagel be used for patients who are not on dialysis?

Renagel's approved use is for the control of high phosphate levels in adult patients with Chronic Kidney Disease (CKD) who are on dialysis. Official studies and product information indicate that the safety and effectiveness of the medication have not yet been established for CKD patients who are not receiving dialysis treatment.

Q: Can I crush Renagel tablets if I have trouble swallowing?

According to regulatory guidelines, the film-coated tablets must be swallowed whole and should not be crushed, chewed, or broken. This is necessary because the contents of the tablet expand when wet. The product label suggests that the suspension formulation may be considered for patients with a history of swallowing disorders.

Q: Is Renagel a form of dialysis?

No, Renagel is a prescription medication chemically classified as a phosphate binder. It works locally in the digestive tract to bind phosphate from food, preventing it from being absorbed. It is used as a supportive oral therapy for patients, including those who are already undergoing the medical procedure of dialysis.

How should Renagel be stored and disposed of?

How to Store and Dispose of Renagel?

Official instructions for Renagel storage focus on temperature control, moisture protection, and safety, as detailed in regulatory documents.

Requirement Type	Official Regulatory Statement
Temperature Limit	Do not store above 25 C (77 F).
Moisture Protection	Keep the bottle tightly closed in order to protect the tablets from moisture.
Prohibited Environments	Do not put the medication in the refrigerator or store it in areas prone to heat and moisture, such as a bathroom.
Child Safety	Must be kept out of the sight and reach of children (mandatory safety instruction).
Disposal Mandate	Do not throw away unused or expired medicine via wastewater or household waste. Dispose of the product in accordance with local requirements.